Literature DB >> 26933875

Specifying and Pilot Testing Quality Measures for the American Society of Addiction Medicine's Standards of Care.

Alex H S Harris1, Constance M Weisner, Mady Chalk, Victor Capoccia, Cheng Chen, Cindy Parks Thomas.   

Abstract

OBJECTIVES: In 2013, the American Society of Addiction Medicine (ASAM) approved its Standards of Care for the Addiction Specialist Physician. Subsequently, an ASAM Performance Measures Panel identified and prioritized the standards to be operationalized into performance measures. The goal of this study is to describe the process of operationalizing 3 of these standards into quality measures, and to present the initial measure specifications and results of pilot testing these measures in a large health care system. By presenting the process rather than just the end results, we hope to shed light on the measure development process to educate, and also to stimulate debate about the decisions that were made.
METHODS: Each measure was decomposed into major concepts. Then each concept was operationalized using commonly available administrative data sources. Alternative specifications examined and sensitivity analyses were conducted to inform decisions that balanced accuracy, clinical nuance, and simplicity. Using data from the US Veterans Health Administration (VHA), overall performance and variation in performance across 119 VHA facilities were calculated.
RESULTS: Three measures were operationalized and pilot tested: pharmacotherapy for alcohol use disorder, pharmacotherapy for opioid use disorder, and timely follow-up after medically managed withdrawal (aka detoxification). Each measure was calculable with available data, and showed ample room for improvement (no ceiling effects) and wide facility-level variability.
CONCLUSIONS: Next steps include conducting feasibility and pilot testing in other health care systems and other contexts such as standalone addiction treatment programs, and also to study the specification and predictive validity of these measures.

Entities:  

Mesh:

Year:  2016        PMID: 26933875      PMCID: PMC5001552          DOI: 10.1097/ADM.0000000000000203

Source DB:  PubMed          Journal:  J Addict Med        ISSN: 1932-0620            Impact factor:   3.702


  10 in total

1.  Possible Alternatives to Diagnosis-Based Denominators for Addiction Treatment Quality Measures.

Authors:  Alex H S Harris; Anna D Rubinsky; Katherine J Hoggatt
Journal:  J Subst Abuse Treat       Date:  2015-06-19

2.  Comparing alternative specifications of quality measures: access to pharmacotherapy for alcohol use disorders.

Authors:  Sara Fernandes-Taylor; Alex H S Harris
Journal:  J Subst Abuse Treat       Date:  2011-08-11

3.  A meta-analysis of topiramate's effects for individuals with alcohol use disorders.

Authors:  Janet C Blodgett; A C Del Re; Natalya C Maisel; John W Finney
Journal:  Alcohol Clin Exp Res       Date:  2014-05-05       Impact factor: 3.455

4.  Examining the Specification Validity of the HEDIS Quality Measures for Substance Use Disorders.

Authors:  Alex H S Harris; Laura Ellerbe; Tyler E Phelps; John W Finney; Thomas Bowe; Shalini Gupta; Steven M Asch; Keith Humphreys; Jodie Trafton
Journal:  J Subst Abuse Treat       Date:  2015-01-15

5.  Advancing performance measures for use of medications in substance abuse treatment.

Authors:  Cindy Parks Thomas; Deborah W Garnick; Constance M Horgan; Frank McCorry; Amanda Gmyrek; Mady Chalk; David R Gastfriend; Suzanne Gelber Rinaldo; Joann Albright; Victor A Capoccia; Alex H S Harris; Henrick J Harwood; Pamela Greenberg; Tami L Mark; Huong Un; Marla Oros; Mark Stringer; James Thatcher
Journal:  J Subst Abuse Treat       Date:  2010-10-08

6.  Targeted use of naltrexone without prior detoxification in the treatment of alcohol dependence: a factorial double-blind, placebo-controlled trial.

Authors:  P Heinälä; H Alho; K Kiianmaa; J Lönnqvist; K Kuoppasalmi; J D Sinclair
Journal:  J Clin Psychopharmacol       Date:  2001-06       Impact factor: 3.153

Review 7.  Meta-analysis of naltrexone and acamprosate for treating alcohol use disorders: when are these medications most helpful?

Authors:  Natalya C Maisel; Janet C Blodgett; Paula L Wilbourne; Keith Humphreys; John W Finney
Journal:  Addiction       Date:  2012-10-17       Impact factor: 6.526

Review 8.  Pharmacotherapy for adults with alcohol use disorders in outpatient settings: a systematic review and meta-analysis.

Authors:  Daniel E Jonas; Halle R Amick; Cynthia Feltner; Georgiy Bobashev; Kathleen Thomas; Roberta Wines; Mimi M Kim; Ellen Shanahan; C Elizabeth Gass; Cassandra J Rowe; James C Garbutt
Journal:  JAMA       Date:  2014-05-14       Impact factor: 56.272

9.  Validation of the treatment identification strategy of the HEDIS addiction quality measures: concordance with medical record review.

Authors:  Alex H S Harris; Rachelle N Reeder; Laura S Ellerbe; Thomas R Bowe
Journal:  BMC Health Serv Res       Date:  2011-04-11       Impact factor: 2.655

10.  Disulfiram efficacy in the treatment of alcohol dependence: a meta-analysis.

Authors:  Marilyn D Skinner; Pierre Lahmek; Héloïse Pham; Henri-Jean Aubin
Journal:  PLoS One       Date:  2014-02-10       Impact factor: 3.240

  10 in total
  16 in total

1.  Inpatient adoption of medications for alcohol use disorder: A mixed-methods formative evaluation involving key stakeholders.

Authors:  Paul J Joudrey; Benjamin J Oldfield; Kimberly A Yonkers; Patrick G O'Connor; Gretchen Berland; E Jennifer Edelman
Journal:  Drug Alcohol Depend       Date:  2020-06-02       Impact factor: 4.492

2.  Barriers and Facilitators to Implementation of Pharmacotherapy for Opioid Use Disorders in VHA Residential Treatment Programs.

Authors:  Andrea K Finlay; Jessie J Wong; Laura S Ellerbe; Anna Rubinsky; Shalini Gupta; Thomas R Bowe; Eric M Schmidt; Christine Timko; Jennifer L Burden; Alex H S Harris
Journal:  J Stud Alcohol Drugs       Date:  2018-11       Impact factor: 2.582

3.  Effects of Global Payment and Accountable Care on Medication Treatment for Alcohol and Opioid Use Disorders.

Authors:  Julie M Donohue; Colleen L Barry; Elizabeth A Stuart; Shelly F Greenfield; Zirui Song; Michael E Chernew; Haiden A Huskamp
Journal:  J Addict Med       Date:  2018 Jan/Feb       Impact factor: 3.702

4.  Association between process measures and mortality in individuals with opioid use disorders.

Authors:  Katherine E Watkins; Susan M Paddock; Teresa J Hudson; Songthip Ounpraseuth; Amy M Schrader; Kimberly A Hepner; Bradley D Stein
Journal:  Drug Alcohol Depend       Date:  2017-06-27       Impact factor: 4.492

5.  Logic Model of the Department of Veterans Affairs' Role in Veterans Treatment Courts.

Authors:  Andrea K Finlay; Sean Clark; Jessica Blue-Howells; Sherri Claudio; Matthew Stimmel; Jack Tsai; Alec Buchanan; Joel Rosenthal; Alex H S Harris; Susan Frayne
Journal:  Drug Court Rev       Date:  2019

6.  Agency-level financial incentives and electronic reminders to improve continuity of care after discharge from residential treatment and detoxification.

Authors:  Andrea Acevedo; Margaret T Lee; Deborah W Garnick; Constance M Horgan; Grant A Ritter; Lee Panas; Kevin Campbell; Jason Bean-Mortinson
Journal:  Drug Alcohol Depend       Date:  2017-12-16       Impact factor: 4.492

7.  Facility-level changes in receipt of pharmacotherapy for opioid use disorder: Implications for implementation science.

Authors:  Andrea K Finlay; Ingrid A Binswanger; Christine Timko; David Smelson; Matthew A Stimmel; Mengfei Yu; Tom Bowe; Alex H S Harris
Journal:  J Subst Abuse Treat       Date:  2018-10-02

8.  Access to treatment for alcohol use disorders following Oregon's health care reforms and Medicaid expansion.

Authors:  Dennis McCarty; Yifan Gu; Stephanie Renfro; Robin Baker; Bonnie K Lind; K John McConnell
Journal:  J Subst Abuse Treat       Date:  2018-08-07

9.  Rural Clients' Continuity Into Follow-Up Substance Use Disorder Treatment: Impacts of Travel Time, Incentives, and Alerts.

Authors:  Deborah W Garnick; Constance M Horgan; Andrea Acevedo; Margaret T Lee; Lee Panas; Grant A Ritter; Kevin Campbell
Journal:  J Rural Health       Date:  2019-05-15       Impact factor: 4.333

Review 10.  Developing an opioid use disorder treatment cascade: A review of quality measures.

Authors:  Arthur Robin Williams; Edward V Nunes; Adam Bisaga; Harold A Pincus; Kimberly A Johnson; Aimee N Campbell; Remien H Remien; Stephen Crystal; Peter D Friedmann; Frances R Levin; Mark Olfson
Journal:  J Subst Abuse Treat       Date:  2018-06-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.